Condition
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) clinical trials that are recruiting, at sites in 2 countries (most in United States (3), China (1)). By phase: Phase 1/2 (2), Phase 2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Chidamide, sintilimab and bevacizumab as second-line treatment for advanced extrapulmonary neuroendocrine carcinoma | Phase 2 | Guangzhou, Guangdong | Recruiting | Apr 8, 2026 |
| First-in-human ML261 CAR T therapy for relapsed/refractory SCLC and select neuroendocrine cancers | Phase 1 | St Louis, Missouri and 6 other locations | Recruiting | Mar 23, 2026 |
| DLL3-targeted alpha radiotherapy ([212Pb]Pb-MP0712) for advanced small cell lung cancer and DLL3-positive neuroendocrine tumors | Phase 1/2 | Tampa, Florida and 7 other locations | Recruiting | Dec 12, 2025 |
| Testing Peluntamig for Neuroendocrine Carcinomas | Phase 1/2 | Duarte, California and 14 other locations | Recruiting | Dec 15, 2022 |
All recruiting trials (4)
-
Chidamide, sintilimab and bevacizumab as second-line treatment for advanced extrapulmonary neuroendocrine carcinoma
This trial tests whether the combination of chidamide, sintilimab, and bevacizumab can shrink tumors in adults with advanced extrapulmonary neuroendocrine carcinoma who progressed after first-line therapy.
-
First-in-human ML261 CAR T therapy for relapsed/refractory SCLC and select neuroendocrine cancers
This early-phase study tests whether a patient’s own ML261 CAR T cells can be safely given to see if they help people with relapsed or refractory SCLC or certain neuroendocrine cancers.
-
DLL3-targeted alpha radiotherapy ([212Pb]Pb-MP0712) for advanced small cell lung cancer and DLL3-positive neuroendocrine tumors
This will test a DLL3-targeted radioactive drug ([212Pb]Pb-MP0712) to see if it's safe and can shrink tumors in adults with advanced small cell lung cancer or other DLL3-positive neuroendocrine cancers.
-
Testing Peluntamig for Neuroendocrine Carcinomas
This study is testing a new drug called Peluntamig to see if it can safely help people with different types of neuroendocrine cancers, either on its own or with chemotherapy.
Related topics
Quick answers
How many Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (3 trials), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 2, Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.